3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
16
Prostatic Neoplasms
11
Obesity
8
Sarcopenia
6
Colorectal Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Polycystic Ovary Syndrome
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Hematopoietic and Lymphatic System Neoplasm
2
Interventions
Cyclophosphamide
193
fludarabine phosphate
121
Peripheral Blood Stem Cell Transplantation
106
Etoposide
106
Mycophenolic Acid
94
Filgrastim
91
Doxorubicin
85
Whole-Body Irradiation
83
Tacrolimus
80
Melphalan
78
Brentuximab Vedotin
77
Busulfan
74
Radiotherapy
73
fludarabine
67
Cyclosporine
67
Vinblastine
65
Rituximab
60
Dacarbazine
56
Granulocyte Colony-Stimulating Factor
53
Gemcitabine
52
Antilymphocyte Serum
51
Bleomycin
50
Nivolumab
47
Methotrexate
47
Vincristine
46
Prednisone
45
Cytarabine
43
pembrolizumab
36
Carmustine
36
Bendamustine Hydrochloride
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hodgkin Disease
×
Resistance Training
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled